|
FAM65A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
2.51830000186359E-08 |
| Normal-vs-Stage3 |
1.66533453693773E-15 |
| Normal-vs-Stage4 |
1.62847513252018E-12 |
| Stage1-vs-Stage2 |
3.270600E-01 |
| Stage1-vs-Stage3 |
9.442100E-02 |
| Stage1-vs-Stage4 |
1.962380E-02 |
| Stage2-vs-Stage3 |
7.403800E-02 |
| Stage2-vs-Stage4 |
1.720470E-02 |
| Stage3-vs-Stage4 |
4.138200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.15749999998849E-06 |
| Normal-vs-Asian |
3.01869995666948E-09 |
| Caucasian-vs-AfricanAmerican |
4.104400E-01 |
| Caucasian-vs-Asian |
7.546100E-02 |
| AfricanAmerican-vs-Asian |
7.237000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.25566224085105E-13 |
| Normal-vs-Female |
1.6242562850266E-12 |
| Male-vs-Female |
5.286800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.63391522534084E-12 |
| Normal-vs-Age(81-100Yrs) |
3.817900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.151600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.556600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.844400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.313600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.683600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.595400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.002950E-04 |
| Classical-VS-Follicular |
3.450200E-01 |
| Classical-VS-Other |
8.955800E-02 |
| Classical-VS-Normal |
1.6242562850266E-12 |
| Tall-VS-Follicular |
1.155960E-04 |
| Tall-VS-Other |
7.793000E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
6.912300E-02 |
| Follicular-VS-Normal |
6.7813976656339E-11 |
| Other-VS-Normal |
7.8540000003624E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.55431223447522E-15 |
| Normal-vs-N1 |
1.65423230669148E-14 |
| N0-vs-N1 |
8.724200E-03 |
|
|
